Prognostic Significance of CD30 Expression and Response to Brentuximab Vedotin in Patients with Angioimmunoblastic T Cell Lymphoma

被引：0
|
作者：
Elias, Alexandra [1 ]
Marques-Piubelli, Mario L. [2 ]
Nair, Ranjit [3 ]
Prakash, Rishab [4 ]
Ahmed, Sairah [4 ]
Malpica, Luis
Lee, Hun Ju [4 ]
Xu, Jie [6 ]
Flowers, Christopher R. [4 ]
Neelapu, Sattva S. [4 ,6 ]
Vega, Francisco
Miranda, Roberto [6 ]
Iyer, Swami P. [5 ]
机构：
[1] McGovern Med Sch, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Pearland, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Lymphoma & Myeloma, Houston, TX USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187939
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
    Jagadeesh, Deepa
    Horwitz, Steve
    Bartlett, Nancy L.
    Kim, Youn
    Jacobsen, Eric
    Duvic, Madeleine
    Little, Meredith
    Trepicchio, William
    Fenton, Keenan
    Onsum, Matthew
    Lisano, Julie
    Advani, Ranjana
    ONCOLOGIST, 2022, 27 (10): : 864 - 873
  • [2] CD30 Expression Does Not Predict Response To Brentuximab Vedotin
    Xu, Mina
    Katz, Samuel
    MODERN PATHOLOGY, 2015, 28 : 389A - 389A
  • [3] Expression of CD30 as a biomarker to predict response to brentuximab vedotin
    Xu, Mina L.
    Acevedo-Gadea, Carlos
    Seropian, Stuart
    Katz, Samuel G.
    HISTOPATHOLOGY, 2016, 69 (01) : 155 - 158
  • [4] CD30 Expression Does Not Predict Response To Brentuximab Vedotin
    Xu, Mina
    Katz, Samuel
    LABORATORY INVESTIGATION, 2015, 95 : 389A - 389A
  • [5] Selection For Brentuximab Vedotin Resistant Lymphoma Cell Lines Leads To Downregulation Of Surface CD30 Expression
    Chen, Robert
    Hou, Jessie
    Reddy, Megan
    Newman, Edward
    Forman, Stephen J.
    Kane, Susan
    BLOOD, 2013, 122 (21)
  • [6] Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma
    Alperovich, Anna
    Younes, Anas
    CANCER JOURNAL, 2016, 22 (01): : 23 - 26
  • [7] Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma
    Wang, Guan-Nan
    Zhao, Wu-Gan
    Li, Ling
    Zhang, Dan-Dan
    Gao, Xian-Zheng
    Zhou, Jun
    Zhang, Lei
    Fu, Xiao-Rui
    Zheng, Xiang-Yu
    Li, Ye
    Li, Zhen
    Zhang, Ming-Zhi
    Li, Wen-Cai
    ONCOLOGY LETTERS, 2017, 13 (03) : 1211 - 1215
  • [8] Prognostic Role of CD30 From a Retrospective Review of 295 Patients with Angioimmunoblastic T-Cell Lymphoma
    Mohamed, Shehab
    Parrish, Julia
    Khan, Maliha
    Premji, Sarah
    Elias, Alexander
    Malpica, Luis
    Nair, Ranjit
    Chihara, Dai
    Srour, Samer
    Miranda, Roberto
    Xu, Jie
    Vega, Francisco
    Iyer, Sawminathan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S414 - S414
  • [9] Recent Advances in Understanding the Clinical Responses of Brentuximab Vedotin in Lymphoma and the Correlation with CD30 Expression
    Chen, Wen
    Zhang, Zhihong
    ONCOTARGETS AND THERAPY, 2025, 18 : 1 - 14
  • [10] Is CD30 a predictive biomarker for brentuximab vedotin?
    Chen, Robert
    LEUKEMIA & LYMPHOMA, 2017, 58 (07) : 1524 - 1525
12345